Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $912000.0.

  • Sangamo Therapeutics' Short-term Investments changed N/A to $912000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $912000.0, marking a year-over-year change of. This contributed to the annual value of $197.7 million for FY2021, which is 6124.71% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Short-term Investments of $912000.0 as of Q3 2025.
  • Sangamo Therapeutics' 5-year Short-term Investments high stood at $464.1 million for Q1 2021, and its period low was $912000.0 during Q3 2025.
  • In the last 5 years, Sangamo Therapeutics' Short-term Investments had a median value of $197.7 million in 2021 and averaged $185.1 million.
  • Per our database at Business Quant, Sangamo Therapeutics' Short-term Investments soared by 8224.76% in 2021 and then crashed by 6548.05% in 2023.
  • Over the past 5 years, Sangamo Therapeutics' Short-term Investments (Quarter) stood at $197.7 million in 2021, then rose by 10.79% to $219.0 million in 2022, then crashed by 65.48% to $75.6 million in 2023, then tumbled by 98.79% to $916000.0 in 2024, then fell by 0.44% to $912000.0 in 2025.
  • Its last three reported values are $912000.0 in Q3 2025, $916000.0 for Q1 2024, and $75.6 million during Q3 2023.